Assessing New RAF-Directed Drugs in Melanoma

Data from the phase I KN-8701 trial suggest that combining exarafenib, an investigational pan-RAF inhibitor, with the MEK agent binimetinib is a reasonable second-line option for NRAS-mutant melanoma. Meanwhile, in a substudy of the phase I/II FIRELIGHT-1 trial, the type II RAF inhibitor tovorafenib appears active against not only RAF fusion-positive relapsed/refractory melanoma, but central nervous system tumors as well.